These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 19124381)

  • 1. Surfactant respiratory therapy using Surfaxin/sinapultide.
    Lal MK; Sinha SK
    Ther Adv Respir Dis; 2008 Oct; 2(5):339-44. PubMed ID: 19124381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome.
    Sinha SK; Lacaze-Masmonteil T; Valls i Soler A; Wiswell TE; Gadzinowski J; Hajdu J; Bernstein G; Sanchez-Luna M; Segal R; Schaber CJ; Massaro J; d'Agostino R;
    Pediatrics; 2005 Apr; 115(4):1030-8. PubMed ID: 15805381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. One-year follow-up of very preterm infants who received lucinactant for prevention of respiratory distress syndrome: results from 2 multicenter randomized, controlled trials.
    Moya F; Sinha S; Gadzinowski J; D'Agostino R; Segal R; Guardia C; Mazela J; Liu G;
    Pediatrics; 2007 Jun; 119(6):e1361-70. PubMed ID: 17533176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lucinactant for the prevention of respiratory distress syndrome in premature infants.
    Jordan BK; Donn SM
    Expert Rev Clin Pharmacol; 2013 Mar; 6(2):115-21. PubMed ID: 23473590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of exogenous pulmonary surfactants on mortality rate in neonatal respiratory distress syndrome: A network meta-analysis of randomized controlled trials.
    Zhang L; Cao HY; Zhao S; Yuan LJ; Han D; Jiang H; Wu S; Wu HM
    Pulm Pharmacol Ther; 2015 Oct; 34():46-54. PubMed ID: 26296793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lucinactant for the treatment of respiratory distress syndrome in neonates.
    Piehl E; Fernandez-Bustamante A
    Drugs Today (Barc); 2012 Sep; 48(9):587-93. PubMed ID: 23032799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lucinactant: a novel synthetic surfactant for the treatment of respiratory distress syndrome.
    Donn SM
    Expert Opin Investig Drugs; 2005 Mar; 14(3):329-34. PubMed ID: 15833063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants.
    Moya FR; Gadzinowski J; Bancalari E; Salinas V; Kopelman B; Bancalari A; Kornacka MK; Merritt TA; Segal R; Schaber CJ; Tsai H; Massaro J; d'Agostino R;
    Pediatrics; 2005 Apr; 115(4):1018-29. PubMed ID: 15805380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surfactant and respiratory distress syndrome.
    Milner AD
    Turk J Pediatr; 1996; 38(1):37-43. PubMed ID: 8819619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Exogenous surfactant therapy: new synthetic surfactants].
    Lacaze-Masmonteil T
    Arch Pediatr; 2008 Jun; 15 Suppl 1():S42-6. PubMed ID: 18822258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein containing synthetic surfactant versus animal derived surfactant extract for the prevention and treatment of respiratory distress syndrome.
    Pfister RH; Soll RF; Wiswell T
    Cochrane Database Syst Rev; 2007 Jul; (3):CD006069. PubMed ID: 17636826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein containing synthetic surfactant versus animal derived surfactant extract for the prevention and treatment of respiratory distress syndrome.
    Pfister RH; Soll RF; Wiswell T
    Cochrane Database Syst Rev; 2007 Oct; (4):CD006069. PubMed ID: 17943881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Animal-derived surfactants versus past and current synthetic surfactants: current status.
    Moya F; Maturana A
    Clin Perinatol; 2007 Mar; 34(1):145-77, viii. PubMed ID: 17394936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolution of pulmonary surfactants for the treatment of neonatal respiratory distress syndrome and paediatric lung diseases.
    Mazela J; Merritt TA; Gadzinowski J; Sinha S
    Acta Paediatr; 2006 Sep; 95(9):1036-48. PubMed ID: 16938747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Colfosceril palmitate (Exosurf)--artificial surfactant for immature lungs.
    Drug Ther Bull; 1991 Jun; 29(12):46. PubMed ID: 1935584
    [No Abstract]   [Full Text] [Related]  

  • 16. Surfactant trials.
    Moya FR; Sinha SK; D'Agostino R
    Pediatrics; 2006 Jan; 117(1):245-7; author reply 247-8. PubMed ID: 16396889
    [No Abstract]   [Full Text] [Related]  

  • 17. Surfactant therapy in respiratory distress syndrome--the first local experience.
    Lim NL; Nordin MM; Cheah IG
    Med J Malaysia; 1994 Mar; 49(1):4-11. PubMed ID: 8057989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute and sustained effects of lucinactant versus poractant-alpha on pulmonary gas exchange and mechanics in premature lambs with respiratory distress syndrome.
    Gastiasoro-Cuesta E; Alvarez-Diaz FJ; Rey-Santano C; Arnaiz-Renedo A; Loureiro-Gonzalez B; Valls-i-Soler A
    Pediatrics; 2006 Feb; 117(2):295-303. PubMed ID: 16452346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lucinactant: in neonatal respiratory distress syndrome.
    Moen MD; Perry CM; Wellington K
    Treat Respir Med; 2005; 4(2):139-45; discussion 146-7. PubMed ID: 15813666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Animal derived surfactant extract versus protein free synthetic surfactant for the prevention and treatment of respiratory distress syndrome.
    Ardell S; Pfister RH; Soll R
    Cochrane Database Syst Rev; 2015 May; (5):CD000144. PubMed ID: 26009996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.